BRNS Barinthus Biotherapeutics Corp: Net earnings per share for the last 12 months

Barinthus Biotherapeutics (BRNS) automates the discovery of drugs for T-cell pathologies using AI and robotics, replacing manual bioscreening. Intellectual property protection is ensured by patents on viral vectors and high R&D expenditures. The company is currently focusing on tests for Hepatitis B and HPV therapies to preserve liquidity. The price action of the securities on GURU.Markets with an EPS of 41.80 confirms these fundamental shifts.
Barinthus Biotherapeutics - analytical breakdowns and key metrics (BRNS)

Barinthus Biotherapeutics (BRNS) ensures strict temperature control during the air transport of innovative immunotherapeutic drugs to preserve their properties. By analyzing the year-over-year EPS (TTM) comparison, an investor assesses the net growth dynamics of earnings per share over twelve months, which allows for the identification of a sustainable margin growth trend despite debt service risks and currency fluctuations.